thyn1 Antibody

Apoptosis and Cellular Stress

• THYN1 modulates apoptosis, with studies linking its expression to stress-induced cell death .

• Knockout mice show impaired immune responses and retinal development, underscoring its regulatory role .

T-Cell Activation and Immunity

• Anti-Thy-1 antibodies inhibit T-cell proliferation by targeting nonpolymorphic epitopes, suggesting THYN1’s involvement in immune signaling .

• In murine models, Thy-1 antibodies block mixed lymphocyte reactions without complement, highlighting its role in inflammation-driven pathways .

Angiogenesis and Disease

• Thy-1 is upregulated in adult angiogenesis (e.g., post-injury vasculature, tumor-associated vessels) but absent in embryonic angiogenesis .

• Cytokines like IL-1β and TNF-α induce THYN1 expression, linking it to inflammatory angiogenesis .

Western Blot (WB)

• Detects THYN1 at ~26–32 kDa in lysates from HEK-293, LNCaP, and Jurkat cells .

• Example: Proteintech’s 68337-1-Ig antibody shows a clear band at 28 kDa in human cell lines .

Immunohistochemistry (IHC)

• Localizes THYN1 in nuclei of human lung cancer tissues and mouse testis .

• Optimization: Antigen retrieval with TE buffer (pH 9.0) enhances signal clarity .

Functional Studies

• Anti-THYN1 antibodies block hematopoietic progenitor expansion in serum-free cultures, indicating a role in primitive cell regulation .

• Soluble THYN1 retains GPI anchors in body fluids, suggesting its utility as a biomarker in autoimmune and inflammatory conditions .

Technical Considerations

• Cross-Reactivity: Rabbit polyclonal antibodies (e.g., A13785) show broad species reactivity, while monoclonal variants (e.g., 68337-1-Ig) are human/mouse-specific .

• Controls: Recombinant THYN1-Ig fusion proteins validate antibody specificity in blocking experiments .

• Limitations: Some antibodies (e.g., ab243822) exhibit batch-dependent variability in immunohistochemistry .

Clinical and Research Implications

• Cancer: THYN1 is overexpressed in lymphoma and correlates with tumor angiogenesis .

• Autoimmunity: Linked to dysregulated T-cell responses in rheumatoid arthritis and lupus .

• Therapeutic Potential: Targeting THYN1 with monoclonal antibodies could modulate pathological angiogenesis or immune activation .